Effects of Serotonin Transporter Promoter Polymorphisms on Serotonin Function

The serotonin transporter promoter polymorphism (5-HTTLPR) has been associated with vulnerability to stress-induced depressive symptoms and with the speed and rate of response to antidepressant treatment. The goal of the present study was to evaluate the association between the 5-HTTLPR and the functional response of the serotonin system as measured by the neuroendocrine and cerebral metabolic response to intravenous administration of the selective serotonin reuptake inhibitor citalopram in normal control subjects. Genotyping was performed for 5-HTTLPR insertion/deletion polymorphism long (l) and short (s) variant alleles. The ll genotype was compared with the combined sl+ss and with the ss genotype alone. Citalopram plasma concentrations did not differ significantly between groups. The s allele was associated with a less of an increase in prolactin and cortisol than the ll genotype. The s allele was associated with greater decreases in left frontal, precentral and middle temporal gyri compared to the ll genotype. The ll genotype was associated with greater decreases in right frontal, insula and superior temporal gyrus compared to the ss genotype. These findings suggest that 5-HTTLPR is associated with an altered functional response of the serotonin system, which may represent a neurobiologic substrate for the differential response to antidepressant treatment in late life and the emergence of neuropsychiatric symptoms in neurodegenerative disorders.

[1]  Carolyn C Meltzer,et al.  A fenfluramine-activated FDG-PET study of borderline personality disorder , 2000, Biological Psychiatry.

[2]  Shitij Kapur,et al.  Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET , 2001, Neuropsychopharmacology.

[3]  Do genetic polymorphisms of serotonin (5‐HT) neurotransmission influence function in humans? , 2003, American journal of medical genetics. Part A.

[4]  B Müller-Oerlinghausen,et al.  Serotonin transporter polymorphisms: no association with response to antipsychotic treatment, but associations with the schizoparanoid and residual subtypes of schizophrenia , 2001, Molecular Psychiatry.

[5]  J M Gorman,et al.  Cerebral glucose metabolism in women with panic disorder. , 1998, The American journal of psychiatry.

[6]  S. Delbrück,et al.  A novel allelic variant of the human serotonin transporter gene regulatory polymorphism. , 1997, Cytogenetics and cell genetics.

[7]  M. Egan,et al.  Serotonin Transporter Genetic Variation and the Response of the Human Amygdala , 2002, Science.

[8]  Paul J. Harrison,et al.  Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine , 2000, Psychopharmacology.

[9]  Yoshiro Okubo,et al.  No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET , 2003, Synapse.

[10]  G. Aghajanian,et al.  The electrophysiology of prefrontal serotonin systems: therapeutic implications for mood and psychosis , 1998, Biological Psychiatry.

[11]  A. Schatzberg,et al.  Pharmacogenetics of antidepressant medication intolerance. , 2003, The American journal of psychiatry.

[12]  D. Kupfer,et al.  Allelic Variation in the Serotonin Transporter Promoter Affects Onset of Paroxetine Treatment Response in Late-Life Depression , 2000, Neuropsychopharmacology.

[13]  Patrick Dupont,et al.  Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging , 1996, Psychiatry Research: Neuroimaging.

[14]  D. Kupfer,et al.  Serotonin in Aging, Late-Life Depression, and Alzheimer's Disease: The Emerging Role of Functional Imaging , 1998, Neuropsychopharmacology.

[15]  K. Lesch,et al.  Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF) , 2000, Neurochemistry International.

[16]  M. Diego,et al.  CES‐D depression scores are correlated with frontal EEG alpha asymmetry , 2001, Depression and anxiety.

[17]  S Debener,et al.  Allelic variation in serotonin transporter function associated with the intensity dependence of the auditory evoked potential , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[18]  B. Pollock,et al.  The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease , 2001, International Psychogeriatrics.

[19]  B. Carroll,et al.  Serotonin transporter gene polymorphism and antidepressant response , 2000, Neuroreport.

[20]  Anna Barnes,et al.  Serotonin modulation of cerebral glucose metabolism in normal aging , 2004, Neurobiology of Aging.

[21]  P. Riederer,et al.  Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease , 2001, Molecular Psychiatry.

[22]  B. Pollock,et al.  Polymorphism of the Serotonin Transporter , 2001 .

[23]  R. Davidson.  Emotion and Affective Style: Hemispheric Substrates , 1992 .

[24]  Vijay Dhawan,et al.  Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects , 2002, Synapse.

[25]  K. Gołembiowska,et al.  Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. , 2000, Polish journal of pharmacology.

[26]  B. Pollock,et al.  The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. , 2001, Archives of neurology.

[27]  R Myers,et al.  Effect of 5‐HT on binding of [11C] WAY 100635 to 5‐HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine , 2001, Synapse.

[28]  M. Ernst,et al.  Cerebral glucose metabolism during pharmacologic studies: test-retest under placebo conditions. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  Michael J. Anderle,et al.  The neural substrates of affective processing in depressed patients treated with venlafaxine. , 2003, The American journal of psychiatry.

[30]  K. Gadde,et al.  Serotonin-Related Gene Polymorphisms and Central Nervous System Serotonin Function* , 2003, Neuropsychopharmacology.

[31]  C. Kelche,et al.  Serotonergic modulation of hippocampal acetylcholine release after long‐term neuronal grafting , 2000, Neuroreport.

[32]  C Reist,et al.  Serotonin transporter promoter polymorphism is associated with attenuated prolactin response to fenfluramine. , 2001, American journal of medical genetics.

[33]  E. Smeraldi,et al.  Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine , 1998, Molecular Psychiatry.

[34]  Thomas E. Nichols,et al.  Positron Emission Tomographic Imaging of Serotonin Activation Effects on Prefrontal Cortex in Healthy Volunteers , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  S. Kapur,et al.  The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET , 1999, Psychopharmacology.

[36]  D. Kupfer,et al.  Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression. , 1999, The American journal of psychiatry.

[37]  H. Edenberg,et al.  Improved method for detecting the long and short promoter alleles of the serotonin transporter gene HTT (SLC6A4). , 1998, Psychiatric genetics.

[38]  Jun Yu Li,et al.  Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome , 2002, Biological Psychiatry.

[39]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[40]  Jean Logan,et al.  Imaging endogenous dopamine competition with [11C]raclopride in the human brain , 1994, Synapse.

[41]  D. Wong,et al.  Cerebral Glucose Utilization Is Reduced in Second Test Session , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  Matthias J. Müller,et al.  Neuroendocrine Effects of a 20-mg Citalopram Infusion in Healthy Males , 1996, Neuropsychopharmacology.

[43]  H. Mayberg,et al.  Remote lateralized changes in cortical [3H]spiperone binding following focal frontal cortex lesions in the rat , 1990, Brain Research.

[44]  J. Douglas Bremner,et al.  Does stress damage the brain? , 1999, Biological Psychiatry.

[45]  R. Samanin,et al.  Effect of 5-HT1A Receptor Antagonists on Citalopram-induced Increase in Extracellular Serotonin in the Frontal Cortex, Striatum and Dorsal Hippocampus , 1997, Neuropharmacology.

[46]  B. Pollock,et al.  Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. , 2001, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[47]  R. Dykes,et al.  Monoamines and their metabolites in somatosensory, visual, and cingulate cortices of adult rat: Differences in content and lack of sidedness , 1990, Neurochemical Research.

[48]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[49]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[50]  D. Murphy,et al.  Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. , 1999, American journal of medical genetics.

[51]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[52]  Y. Mateo,et al.  Inhibition of 5-hydroxytryptamine reuptake by the antidepressant citalopram in the locus coeruleus modulates the rat brain noradrenergic transmission in vivo , 2000, Neuropharmacology.

[53]  I. Lucki,et al.  The presence of a serotonin uptake inhibitor alters pharmacological manipulations of serotonin release , 1993, Neuroscience.

[54]  J D Brodie,et al.  Reproducibility of Cerebral Glucose Metabolic Measurements in Resting Human Subjects , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[55]  K K Kidd,et al.  Population studies of polymorphisms of the serotonin transporter protein gene. , 1999, American journal of medical genetics.

[56]  Andreas Heinz,et al.  A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity , 2000, Biological Psychiatry.

[57]  J S Fowler,et al.  Striatal binding of the PET ligand 11C‐raclopride is altered by drugs that modify synaptic dopamine levels , 1993, Synapse.

[58]  Guillaume Lucas,et al.  Endogenous serotonin enhances the release of dopamine in the striatum only when nigro-striatal dopaminergic transmission is activated , 2000, Neuropharmacology.

[59]  P. Jerabek,et al.  Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response , 2000, Biological Psychiatry.

[60]  B. Langguth,et al.  Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI) , 2003, Psychopharmacology.

[61]  H. Mayberg,et al.  PET imaging of cortical S2 serotonin receptors after stroke: lateralized changes and relationship to depression. , 1988, The American journal of psychiatry.

[62]  B. Pollock,et al.  Plasma levels of citalopram enantiomers and metabolites in elderly patients. , 1997, Psychopharmacology bulletin.

[63]  S. Tsai,et al.  Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders , 2002, Molecular Psychiatry.

[64]  Richard S. J. Frackowiak,et al.  The Mind's Eye—Precuneus Activation in Memory-Related Imagery , 1995, NeuroImage.

[65]  B. Lerer,et al.  Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia , 2003, The Pharmacogenomics Journal.

[66]  P. Fox,et al.  Differential limbic–cortical correlates of sadness and anxiety in healthy subjects: implications for affective disorders , 2000, Biological Psychiatry.

[67]  John J. B. Allen,et al.  Frontal EEG asymmetry and the behavioral activation and inhibition systems. , 2003, Psychophysiology.

[68]  Anna Barnes,et al.  Acute and chronic effects of citalopram on cerebral glucose metabolism in geriatric depression. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[69]  N. Fox,et al.  Relative right frontal EEG activation in 3- to 6-month-old infants of "depressed" mothers. , 1995 .

[70]  V. Dhawan,et al.  Noninvasive quantitative fluorodeoxyglucose PET studies with an estimated input function derived from a population-based arterial blood curve. , 1993, Radiology.

[71]  M. Schindl,et al.  The citalopram challenge test in patients with major depression and in healthy controls , 1999, Psychiatry Research.

[72]  K. Lesch,et al.  Glucocorticoid‐regulated human serotonin transporter (5‐HTT) expression is modulated by the 5‐HTT gene‐promotor‐linked polymorphic region , 2003, Journal of neurochemistry.

[73]  Kurt Hornik,et al.  No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism , 2001, Biological Psychiatry.

[74]  N. Ohashi,et al.  SM‐20220, a Potent Na+/H+ Exchange Inhibitor, Improves Consciousness Recovery and Neurological Outcome Following Transient Cerebral Ischaemia in Gerbils , 2000, The Journal of pharmacy and pharmacology.